Julio M Pow-Sang is an expert in Oncology at Moffitt Cancer Center (United States). As of October 2026, ScienceLeadR ranks Julio M Pow-Sang in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Julio M Pow-Sang has authored 335 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 883 (community average: 125). How the SLR is computed.

LeadR Profile

Julio M Pow-Sang Moffitt Cancer Center United States
883 ScienceLeadR Reputation 883
Network Map

Oncology

Subspecialties: Urology - Radiotherapy - Histology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1987 - 2026

Source: PubMed

Moffitt Cancer Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 335

Citations

Citations: 11 848 1st author: 16 Last author: 60 Unique author: 17


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer.
PMID 42848319 — intelligence, neoplasms, multiple chronic conditions, prostate, biopsy, biomarkers, prostatic neoplasms, artificial intelligence
Clin Cancer Res20260
Patient and Technology Selection for Focal Therapy in Prostate Cancer.
PMID 42449614 — neoplasms, prostate, prostatic neoplasms, therapeutics
Cancers (Basel)20260
Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.
PMID 42082271 — neoplasms, prostate, hormones, immunotherapy, prostatic neoplasms, nivolumab, therapeutics, immunosuppression therapy
J Immunother Cancer20260
Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention.
PMID 42073599 — muscles, androgens, neoplasms, body composition, prostate, biomarkers, prostatic neoplasms, obesity, therapeutics, muscle, skeletal
Cancers (Basel)20260
A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study.
PMID 41671436 — neoplasms, prostate, biopsy, prostatic neoplasms, therapeutics
J Natl Compr Canc Netw20250

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 3
Phase 2 2
Phase 1 1
Phase 1/Phase 2 1

By status:

Completed 4
Active not recruiting 1
Suspended 1
Terminated 1

By type:

Interventional 5
Observational 2

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map